

## Class action authorized for people in Canada who used ABILIFY® and experienced Impulse Control Disorders

A class action has been authorized on behalf of all Canadians who took **ABILIFY®** before February 23, 2017 and developed one or more of the following alleged **Impulse-Control Disorders: PATHOLOGICAL GAMBLING, COMPULSIVE EATING/BINGE EATING, COMPULSIVE SHOPPING OR SPENDING** and/or **HYPERSEXUAL BEHAVIOURS/SEXUAL ADDICTION**.

The representative plaintiff alleges that ABILIFY® causes the above **Impulse-Control Disorders** and that the defendants, Bristol-Myers Squibb Canada Co. and Otsuka Canada Pharmaceutical Inc., gave inadequate warnings about this risk.

The Court has not yet decided whether the defendants have committed a fault, and the claims have not yet been proven in court. However, if you are included in the class action, your rights may be impacted. **If you wish to remain a class member, you have nothing to do.** If you wish to opt out, you have until **May 31<sup>st</sup>, 2020** to advise Class Counsel (identified below) and the clerk of the Superior Court of Quebec, District of Montreal, at 1 Notre Dame Street East, Montreal, Quebec, H2Y 1B6, by registered mail. Please make sure to include file no. 500-06-000831-160 in your correspondence.

You may request a copy of the long version of this notice or simply visit the website below

### FOR MORE INFORMATION

#### Class Counsel

Consumer Law Group Inc.  
1030 rue Berri, Suite 102  
Montréal (Québec) H2L 4C3

[abilify@clg.org](mailto:abilify@clg.org)

(514) 266-7863

1-888-909-7863

[www.clg.org](http://www.clg.org)

#### Central Registry of Class Actions

[www.registredesactionscollectives.quebec/en#](http://www.registredesactionscollectives.quebec/en#)

*Scheer v. Bristol-Myers Squibb Canada Co. et al.*, No. 500-06-000831-160 (District of Montréal)

This notice has been authorized by the Superior Court of Québec